Answers are grounded in this paper and cite their sources.
Findings demonstrate cynaropicrin inhibits migration in triple-negative breast cancer, suggesting therapeutic potential.
The present findings indicated the anti-metastatic capacity of cynaropicrin against TNBC by a mechanism that implicated the inhibition of the EMT and pro-angiogenic factor VEGFA. These outcomes suggest cynaropicrin as an anti-metastatic and anti-angiogenic sesquiterpene lactone against TNBC.
No takes yet. Share an insight, caveat, or question.
Amaral et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: